Physician profile
Hon-Ming Eng
NPI 1477563385
$16,044.90
in general payments reported to CMS, 2019-2025
31 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,443 · 2020: $1,559 · 2021: $2,197 · 2022: $2,987 · 2023: $3,025 · 2024: $2,166 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,840 · Debt Forgiveness: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,840.00 |
| Debt Forgiveness | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $7,159.09 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Qol Medical, LLC | $2,116.71 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $1,053.58 | 2019-2025 | |
| Gilead Sciences, INC. | $702.25 | 2019-2025 | |
| Braintree Laboratories, INC. | $652.35 | 2019-2024 | Suflave, Sutab |
| Celgene Corporation | $600.83 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $442.59 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $434.28 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $309.83 | 2019-2024 | Linzess |
| Daiichi Sankyo INC. | $291.95 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $279.41 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $271.42 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $262.07 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $249.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $214.85 | 2022-2023 | Dificid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $200.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $130.76 | 2021-2023 | |
| Madrigal Pharmaceuticals | $119.36 | 2025 | Rezdiffra |
| Concordia Pharmaceuticals INC. | $111.69 | 2019 | |
| Napo Pharmaceuticals INC | $95.73 | 2019 | |
| Allergan, INC. | $94.34 | 2019-2020 | |
| Exact Sciences Corporation | $54.88 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $52.78 | 2023-2024 | |
| Intra-Sana Laboratories | $21.63 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Biotech, INC. | $21.57 | 2022 | |
| Celltrion USA INC. | $20.59 | 2024 | Vegzelma |
| Olympus America INC. | $20.00 | 2023 | Evis Exera III Gastrointestinal Videoscope |
| Capsovision, INC. | $17.78 | 2025 | Capsocam Plus |
| Aimmune Therapeutics, INC. | $15.74 | 2024 | |
| Intercept Pharmaceuticals, INC. | $14.59 | 2020 | |
| Boston Scientific Corporation | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hon-Ming Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.